ReviewFrontiers in immunology2021
Regulation and Function of Interferon-Lambda (IFNλ) and Its Receptor in Asthma.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Interferon lambda in anti-viral defense and cancer: dual roles, mechanism and therapeutic potential.Journal of translational medicine · 2026Review
- The role of virus in nasal inflammation.European journal of medical research · 2025Review
- PGAP3 regulates human bronchial epithelial cell mRNAs present in asthma and respiratory virus reference data sets.medRxiv : the preprint server for health sciences · 2024Article
- Causality between various cytokines and asthma: a bidirectional two-sample Mendelian randomization analysis.Frontiers in medicine · 2024Article
- Poly I:C Pre-Treatment Induced the Anti-Viral Interferon Response in Airway Epithelial Cells.Viruses · 2023Article
- IL-1 receptor antagonist attenuates proinflammatory responses to rhinovirus in airway epithelium.The Journal of allergy and clinical immunology · 2023Article
- Type I Interferonopathies in Childhood.Balkan medical journal · 2023Article
- Influence of polymorphic variations of IFNL, HLA, and IL-6 genes in severe cases of COVID-19.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Interferon-lambda: New role in intestinal symptoms of COVID-19.World journal of gastroenterology · 2023Review
- After the Storm: Regeneration, Repair, and Reestablishment of Homeostasis Between the Alveolar Epithelium and Innate Immune System Following Viral Lung Injury.Annual review of pathology · 2023Review
- Altered cell function and increased replication of rhinoviruses and EV-D68 in airway epithelia of asthma patients.Frontiers in microbiology · 2023Article
- The role of gut microbiome in the complex relationship between respiratory tract infection and asthma.Frontiers in microbiology · 2023Review
- Type III interferon exerts thymic stromal lymphopoietin in mediating adaptive antiviral immune response.Frontiers in immunology · 2023Review
- Integrated Network Pharmacology and Gut Microbiota Analysis to Explore the Mechanism of Sijunzi Decoction Involved in Alleviating Airway Inflammation in a Mouse Model of Asthma.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Rhinovirus Infection and Virus-Induced Asthma.Viruses · 2022Review
- Innate Immune Responses by Respiratory Viruses, Including Rhinovirus, During Asthma Exacerbation.Frontiers in immunology · 2022Review
- Progress in diagnosis and treatment of difficult-to-treat asthma in children.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic respiratory disease affecting people of all ages, especially children, worldwide. Origins of asthma are suggested to be placed in early life with heterogeneous clinical presentation, severity and pathophysiology. Exacerbations of asthma disease can be triggered by many factors, including viral respiratory tract infections. Rhinovirus (RV) induced respiratory infections are the predominant cause of the common cold and also play a crucial role in asthma development and exacerbations. Rhinovirus mainly replicates in epithelial cells lining the upper and lower respiratory tract. Type III interferons, also known as interferon-lambda (IFNλ), are potent immune mediators of resolution of infectious diseases but they are known to be involved in autoimmune diseases as well. The protective role of type III IFNs in antiviral, antibacterial, antifungal and antiprotozoal functions is of major importance for our innate immune system. The IFNλ receptor (IFNλR) is expressed in selected types of cells like epithelial cells, thus orchestrating a specific immune response at the site of viruses and bacteria entry into the body. In asthma, IFNλ restricts the development of TH2 cells, which are induced in the airways of asthmatic patients. Several studies described type III IFNs as the predominant type of interferon increased after infection caused by respiratory viruses. It efficiently reduces viral replication, viral spread into the lungs and viral transmission from infected to naive individuals. Several reports showed that bronchial epithelial cells from asthmatic subjects have a deficient response of type III interferon after RV infection
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.